Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) EPS (Weighted Average and Diluted) (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.84 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed N/A to $0.84 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.27 through Dec 2025, changed N/A year-over-year, with the annual reading at $0.39 for FY2025, 108.9% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.84 at Soleno Therapeutics, up from $0.47 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.84 in Q4 2025, with the low at -$0.95 in Q1 2025.